Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL6074697 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL228157 | 0.95 | — | — | |
| Nitric Acid SCHEMBL2081625 | 0.95 | CA5A (0.80) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL1766012 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL15408318 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL3625728 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL15121484 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL4824217 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL19348276 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 | |
| Nitric Acid SCHEMBL7145284 | 0.91 | CA5A (0.73) | CA5ACA5BMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1011651-B1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6090805-A | Tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-1011651-A1 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | Merck & Co., Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1011651-A4 | METHOD OF TREATING DIABETES AND RELATED DISEASE STATES | MERCK & CO INC (US) | 2000-06-28 | — | — | EP | disclosed |
| US-4411913-A | OTHER SPIRO COMPOUNDS, CARDIOVASCULAR DISORDERS, HYPOTENSIVE, ANTIEDEMIC, ANTILIPEMIC, HYPOGLYCEMIC, ANOREXIGENIC | SANDOZ LTD. (CH) | 1983-10-25 | — | — | US | disclosed |
| US-4237306-A | ELECTROPHILIC REACTIONS WITH ALKYL ARYL KETONES TO PRODUCE METHYL ARYL ALKANOATES | EMERY INDUSTRIES, INC. (US) | 1980-12-02 | — | — | US | disclosed |
| US-4226866-A | BACTERICIDES, ACYLATION | MERCK & CO., INC. (US) | 1980-10-07 | — | — | US | disclosed |
| US-4172955-A | REARRANGMENT OF A CINNAMALDEHYDE TO A PHENYLMALONDIALDEHYDE TETRAMETHYL DISACETAL | EMERY INDUSTRIES, INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4150223-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4107439-A | Process for preparing arylalkanoic acid derivatives | THE UPJOHN COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
| US-4076838-A | ANTIARTHRITIC, ANALGESICS, ANTIPHLOGISTICS | SANDOZ LTD. (CH) | 1978-02-28 | — | — | US | disclosed |
| US-4067823-A | Thallium(III) reagents supported on montmorillonite clay minerals and oxythallation processes for utilizing same | EMERY INDUSTRIES, INC. (US) | 1978-01-10 | — | — | US | disclosed |
| US-4032521-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | CA5A 2094/4885CA5B 2088/4885MEN1 2224/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | CA5A 2094/4885CA5B 2088/4885MEN1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.